ÑÀÖÜ»ù´¡ÖÎÁƶÔÑÀÖÜÑ×»¼Õßö¸¹µÒºÖ×Áö»µËÀÒò×Ó-¦Áº¬Á¿µÄÓ°Ïì ÏÂÔØ±¾ÎÄ

ÁúÔ´ÆÚ¿¯Íø http://www.qikan.com.cn

ÑÀÖÜ»ù´¡ÖÎÁƶÔÑÀÖÜÑ×»¼Õßö¸¹µÒºÖ×Áö»µËÀÒò×Ó-¦Áº¬Á¿µÄÓ°Ïì

×÷ÕߣºÁÖÏ£ºè ³ÂÁè ÎâÙš κ±ó

À´Ô´£º¡¶ÖйúʵÓÃÒ½Ò©¡·2011ÄêµÚ28ÆÚ

¡¾ÕªÒª¡¿ Ä¿µÄ ¹Û²ìÑÀÖÜ»ù´¡ÖÎÁÆÂýÐÔÑÀÖÜÑ×»¼ÕßµÄÁÙ´²ÑÀÖÜÖ¸ÊýºÍö¸¹µÒºÖ×Áö»µËÀÒò×Ó-¦ÁˮƽµÄÓ°Ïì¡£·½·¨ 30ÀýÂýÐÔÑÀÖÜÑ×»¼Õߣ¬ÓÚÖÎÁÆÇ°¡¢ÑÀÖÜ»ù´¡ÖÎÁƺó2Öܼ°10ÖÜÂËÖ½Ìõ·¨ÊÕ¼¯»¼ÑÀö¸¹µÒº£¬²¢¼Ç¼Ïà¹ØµÄÁÙ´²Ö¸±ê£¬°üÀ¨¾ú°ßÖ¸Êý¡¢ÑÀö¸Ö¸Êý¡¢Ì½Õï³öѪ¡¢Ì½ÕïÉî¶ÈºÍÁÙ´²¸½×Åɥʧˮƽ£»·ÅÃâ·¨¼ì²âÖÐö¸¹µÒºTNF-¦Áˮƽ¡£½á¹û ÑÀÖÜ»ù´¡ÖÎÁƺó2Öܼ°10ÖÜÂýÐÔÑÀÖÜÑ×»¼ÕßµÄÁÙ´²ÑÀÖÜÖ¸ÊýºÍö¸¹µÒºTNF-¦ÁˮƽÏÔÖøµÍÓÚÖÎÁÆÇ°¡£½áÂÛ ÑÀÖÜ»ù´¡ÖÎÁÆÄܸÄÉÆÂýÐÔÑÀÖÜÑ×»¼ÕßµÄÁÙ´²ÑÀÖÜÖ¸Êý£¬²¢½µµÍö¸¹µÒºTNF-¦ÁµÄº¬Á¿¡£ ¡¾¹Ø¼ü´Ê¡¿ ÑÀÖÜÑ×;Ö×Áö»µËÀÒò×Ó-¦Á;ÑÀÖÜ»ù´¡ÖÎÁÆ

Effect of Periodontal Initial Therapy on Gingival Crevicular Fluid Tumor Necrosis Factor-alpha In Chronic Periodontitis Patients LIN Xi-hong, CHEN Ling, WU Yun, WEI Bin.Department of stomatology,The No.1 Affiliated Hospital Of Fujian Medical University£¬Fuzhou 350002, China ¡¾Abstract¡¿ Objective This study sought to evaluate the effect of peripodontal initial therapy on gingival crevicular fluid tumor necrosis factor-alpha and on clinical parameters in patients with periodontal disease. Methods Data were obtained from 30 patients diagnosed with chronic

periodontitis. Clinical parameter and GCF samples were obtained at time before, 2 weeks and 10 weeks after pedipodontal initial therapy. GCF was collected using a paper strip£¬and tumor necrosis factor-alpha levels were determined by radioimmunoassay.Results The clinical parameters and tumor necrosis factor-alpha levels in GCF decreased significantly two weeks and ten weeks after

peripodontal initial therapy in patients with periodontal disease. Conclusion Peripodontal initial therapy improved clinical parameters in chronic periodontitis patients accompanied with necrosis factor-alpha levels in GCF decreased.

¡¾Key words¡¿ Periodontitis;Tumor necrosis factor-alpha;Periodental non-surgical treatment

»ù½ðÏîÄ¿£º¸£½¨Ê¡×ÔÈ»¿ÆÑ§»ù½ðÏîÄ¿(ÏîÄ¿±àºÅ£º2008J0276)

Ö×Áö»µËÀÒò×Ó-¦Á(TNF-¦Á)ÊÇÑÀÖÜÑ×Ö¢ºÍÃâÒß·´Ó¦¹ý³ÌÖÐÖØÒªµÄϸ°ûÒò×Ó£¬Ñо¿±íÃ÷ÑÀÖÜÑ×»¼ÑÀTNF-¦ÁˮƽÃ÷ÏÔ¸ßÓÚ½¡¿µ¶ÔÕÕÑÀ£¬ÆäˮƽÓëÑÀÖÜÑ׻ÐÔ¼°ÑÀÖÜ×éÖ¯ÆÆ»µµÄÑÏÖØ³Ì¶È³ÉÕýÏà¹Ø£Û1£Ý¡£ÑÀÖÜ»ù´¡ÖÎÁÆÊÇÖÎÁÆÑÀÖÜÑ×µÄ×î»ù±¾ºÍ×îÓÐЧµÄÖÎÁÆ·½·¨£¬¹Û²ìö¸¹µÒº(gingival

ÁúÔ´ÆÚ¿¯Íø http://www.qikan.com.cn

crevicular fluid£¬GCF)µÄÁ¿ºÍÄÚÈݺ¬Á¿µÄ±ä»¯£¬¶ÔÁ˽âÑÀÖܼ²²¡µÄ²¡Çé±ä»¯£¬ÆÀ¼ÛÖÎÁÆÐ§¹ûÓÐÖØÒªµÄÁÙ´²ÒâÒå£Û2£Ý¡£±¾ÎÄÄâ̽ÌÖÑÀÖÜ»ù´¡ÖÎÁƶԹµö¸ÒºµÄTNF-¦ÁµÄ±ä»¯µÄÓ°Ïì¼°ÆäÓëÑÀÖÜÑ×ÁÙ´²±íÏֵĹØÏµ¡£ 1 ×ÊÁÏÓë·½·¨

1.1 Ò»°ã×ÊÁÏ Ñ¡Ôñ2008Äê7ÔÂÖÁ2011Äê7ÔÂÔÚ¸£½¨Ò½¿Æ´óѧ¸½ÊôµÚÒ»Ò½Ôº¾ÍÕͬÒâ²Î¼Ó±¾ÊÔÑéµÄ·ûºÏÂýÐÔÑÀÖÜÑ×Õï¶Ï±ê×¼£Û3£ÝµÄ»¼Õß30Àý(ÄÐ17Àý£¬Å®13Àý£¬ÄêÁä36~57Ëê)¡£»¼ÕßÎÞÈ«ÉíϵͳÐÔ¼²²¡£¬ÎÞÎüÑÌÊ·£¬ÖÁÉÙ1ÄêδÐÐÑÀÖÜÖÎÁÆ£¬½ü1¸öÔÂÄÚδʹÓÿ¹ÉúËØ¡¢·ÇçÞÌåÒ©Îï»òÆäËûÓ°Ïì°×ϸ°ûµÄÒ©ÎŮÐÔΪ·ÇÔ¾­ÆÚºÍÈÑÉïÆÚ£¬ÎÞ´íò¢»ûÐΣ¬¿ÚÄÚÊ£ÓàÑÀÊý²»ÉÙÓÚ24¿Å£¬ÑÀÖÜ´ü̽ÕïÈ«¿ÚÖÁÉÙ1/3ÒÔÉÏλµã̽ÕïÉî¶È3~4 mm¡£Ã¿Àý»¼Õßѡȡ1~2¸öÑÀÖÜ´ü̽ÕïÉî¶È¡Ý5 mm£¬ÇÒÑÀ¾±²¿ÎÞÈ£ËðºÍ³äÌîÌåµÄºóÑÀΪ¹Û²ì¶ÔÏó¡£ 1.2 ·½·¨

1.2.1 ÖÎÁÆ·½·¨ ËùÓл¼Õß¾ùÐÐÑÀÖÜ»ù´¡ÖÎÁÆ£¬°üÀ¨ÎÀÉúÐû½Ì¡¢ö¸ÉϽàÖκÍö¸Ï¹ÎÖÎ,¸ùÃæÆ½Õû¡£·Ö±ð¼ì²â¾ú°ßÖ¸Êý(PLI)¡¢ÑÀö¸Ö¸Êý(GI)¡¢Ì½Õï³öѪ(BOP)£¬¼Ç¼¹Û²ìÑÀ̽Õï×îÉîλµãµÄ̽ÕïÉî¶È(PD£¬ÑÀÖÜ´üµ×ÖÁö¸ÔµµÄ¾àÀë)¼°ÁÙ´²¸½×Åɥʧ(CAL£¬ÑÀÖÜ´üµ×ÖÁÓÔÑÀ¹ÇÖʽçµÄ¾àÀë)¡£È»ºóÓÃGraceyö¸Ï¹ÎÖÎÆ÷½øÐÐö¸Ï¹ÎÖκ͸ùÃæÆ½ÕûÖÎÁÆ£¬ËùÓÐÁÙ´²²Ù×÷¾ùÓÉͬһÊõÕß½øÐС£2Öܼ°10Öܺó¸´ÕïÔٴμì²éÉÏÊö¸÷ÁÙ´²ÑÀÖÜÖ¸Êý¡£ÎÀÉúÐû½Ì·½·¨:½Ì»á»¼ÕßÕýÈ·µÄË¢ÑÀ·½Ê½£¬¼´ÓÃÈíëÑÀË¢£¬ÒÔˮƽ²ü¶¯·¨Ã¿ÈÕÔç¡¢Íí¸÷Ë¢ÑÀ1´Î£¬Ã¿´Î3 min¡£

1.2.2 Ñù±¾ÊÕ¼¯·½·¨ ·Ö±ðÓÚÑÀÖÜ»ù´¡ÖÎÁÆÇ°¡¢ÖÎÁÆ2Öܼ°10ÖÜÓÃÂËÖ½Ìõ·¨ÊÕ¼¯GCF¡£Öö»¼ÕßÒÔÇåË®Êþ¿Ú£¬½«´ýÈ¡Ñù±¾ÇøÓòÒÔÃÞ¾í¸ôʪ£¬´µ¸ÉÈ¡ÑùÑÀ¼ÕÃæ¼°ÁÚ½üÑÀö¸×éÖ¯£¬ÓýàÖÎÆ÷СÐÄÈ¥³ýö¸ÉϾú°ß£¬½«2 mm¡Á20 mmÎÞ¾úÂËÖ½ÌõÇáÇá²åÈëÈ¡ÑùÑÀ¼Õ²à½ü/Ô¶Öд¦ö¸¹µÄÚ£¬ÖÁÓÐ×èÁ¦Ê±Í£Ö¹£¬30 sºóÈ¡³ö£¬×¼È·¼Ç¼ȡÑùλµã¡£ÈôÂËÖ½ÌõÉÏÓÐÈâÑۿɼûµÄѪ¼£»òմȾÍÙÒºÔòÆúµôÖØÐÂÈ¡Ñù¡£Á¢¼´½«ÂËÖ½Ìõ·ÅÈë2 ml EP¹ÜÖУ¬Öü´æÓÚ-80¡æµÄ±ùÏäÖдýÓá£

1.2.3 ·ÅÉäÃâÒß·¨²â¶¨GCFÖÐTNF-aº¬Á¿ ×°ÓÐÂËÖ½ÌõµÄEP¹Ü×Ô-80¡æ±ùÏäÈ¡³ö£¬·ÅÖÃÓÚÊÒÎÂÏÂ1 h½â¶³£¬Ã¿¹Ü¼ÓÈë500uL pH 7.2µÄPBS»º³åÒº£¬ºãÎÂÕñµ´Æ÷ÉÏÕñµ´1 h£¬¸ßËÙÀëÐÄ»úµÍÎÂÀëÐÄ10 min(4¡æ£¬10000 r/min)±¸Óᣰ´TNF-a·ÅÃâÊÔ¼ÁºÐ˵Ã÷Êé½øÐмì²â¡£

1.3 ͳ¼ÆÑ§·½·¨ ²ÉÓÃSPSS 11.0Êý¾Ý·ÖÎöÈí¼þ£¬ÖÎÁÆÇ°ºóÊý¾ÝÖ®¼äµÄ±È½Ï²ÉÓÃt¼ìÑ飬P 2 ½á¹û

¾­ÑÀÖÜ»ù´¡ÖÎÁƺó2Öܼ°10ÖÜTNF-aµÄˮƽ½ÏÑÀÖÜ»ù´¡ÖÎÁÆÇ°¾ùÃ÷ÏÔ½µµÍ(P 3 ÌÖÂÛ

ÁúÔ´ÆÚ¿¯Íø http://www.qikan.com.cn

ÑÀÖÜÑ×ÊÇÓÉÑÀ¾ú°ßÖеÄ΢ÉúÎïËùÒýÆðµÄÑÀÖÜÖ§³Ö×éÖ¯µÄÂýÐÔ¸ÐȾÐÔ¼²²¡£¬µ¼ÖÂÑÀÖÜÖ§³Ö×éÖ¯µÄÑ×Ö¢¡¢ÑÀÖÜ´üÐγɡ¢½øÐÐÐÔ¸½×ÅɥʧºÍÑÀ²Û¹ÇÎüÊÕ¡£TNF-¦ÁÓëÑÀÖܲ¡±äÖеĽáµÞ×éÖ¯ÆÆ»µ¼°¹ÇÎüÊÕÓйأÛ4£Ý£¬±¾Ñо¿±íÃ÷£¬ÑÀÖÜ»ù´¡ÖÎÁƺó»¼ÕßÑÀÖÜÖ¸ÊýÃ÷ÏÔ¸ÄÉÆ£¬Í¬Ê±°éÓÐGCFÖÐTNF-¦Áº¬Á¿µÄϽµ¡£

ö¸¹µÒºÖк¬ÓдóÁ¿ÑªÇåµ°°×¡¢Ñ×Ö¢½éÖÊ¡¢Î¢ÉúÎï´úл²úÎïºÍø£¬ÆäÖÐTNF-aÊÇÓɵ¥ºË¾ÞÊÉϸ°û²úÉúµÄÒ»ÖֵͷÖ×ÓÁ¿µ°°×ÖÊ£¬ÔÚÑ×Ö¢·´Ó¦ºÍÃâÒßÓ¦´ðÖз¢»ÓÖØÒª×÷Óá£TNF-¦Á×÷ÓÃÓÚ²»Í¬°Ðϸ°û¿ÉÒý·¢¶àÖÖÉúÎïѧЧӦ£º×÷ÓÃÓÚÏËάϸ°û¿É´Ù½øÆäÔöÉú²¢²úÉúPGE2£»×÷ÓÃÓÚѪ¹ÜÄÚÆ¤Ï¸°û£¬¿ÉÔö¼ÓѪ¹Üͨ͸ÐÔ£»×÷ÓÃÓڹǺÍÈí¹Ç×éÖ¯£¬Äܴ̼¤¹ÇÎüÊÕ¼°ÒÖÖÆ¹ÇÐγɡ£TNF-¦Á¿ÉÄܲÎÓëÁËÑÀÖÜÑײ¡±ä¹ý³Ì£Û5£Ý¡£G-¾úÊÇÑÀÖܲ¡µÄÖ÷ÒªÖ²¡¾ú£¬ÄÚ¶¾ËØÊÇG-¾úËù¶ÀÓеÄÒ»ÖÖÖ²¡ÎïÖÊ¡£G-¾úÄÚ¶¾ËصÄÖ÷Òª³É·ÖÖ¬¶àÌÇÊÇÒýÆðTNF-¦ÁÊÍ·ÅµÄÆô¶¯¼Á£¬Ò²ÊÇ»úÌåTNF-¦ÁÉý¸ßµÄÇ¿´Ì¼¤¼Á¡£ÑÀÖÜ»ù´¡ÖÎÁÆ×÷ΪÑÀÖܲ¡ÖÎÁƵĻù±¾ÊֶΣ¬Í¨¹ýÑÀÖÜ»ù´¡ÖÎÁƺͿÚÇ»ÎÀÉúÖ¸µ¼£¬Ìá¸ß»¼Õß¿ÚÇ»±£½¡Òâʶ£¬¸ÄÉÆ»¼Õß¿ÚÇ»ÎÀÉú£¬Ê¹»¼ÕßÑÀÖÜÑ׵ĸ÷ÏîÖ¢×´µÃµ½ºÜºÃµÄ¿ØÖÆ¡£ÑÀÖÜ»ù´¡ÖÎÁƽµµÍGCFÖÐTNF-¦ÁµÄº¬Á¿£¬¿ÉÄÜÓëÆäÖÎÁƺó¼õÉÙG-¾úÖ²¡¾ú¼°ÆäÊͷŵÄÄÚ¶¾ËØ×÷ÓÃÓйأ»¶øTNF-¦Áˮƽ¿Éµ÷¿ØÑ×Ö¢£¬ÆäˮƽµÄ½µµÍ¿É¼õÇá×éÖ¯Ñ×Ö¢ÃâÒß·´Ó¦·¢»Ó¿¹Ñ××÷Óá£

×÷ÕßµÄÑо¿½á¹û±íÃ÷£¬ÂýÐÔÑÀÖÜÑ×»¼Õß½øÐÐÑÀÖÜ»ù´¡ÖÎÁƺó£¬ÔÚ¸ÄÉÆÑÀÖÜÖ¸ÊýµÄͬʱ°éÓÐGCFÖÐTNF-¦Áº¬Á¿µÄϽµ¡£¼øÓÚTNF-¦ÁÔÚÑÀÖÜÑ×·¢²¡ÖеÄÖØÒª×÷Óã¬ÔÚ½øÐÐÑÀÖÜ»ù´¡ÖÎÁÆÊ±ÊÇ·ñÐèҪʹÓÃÒÖÖÆTNF-¦Á·ÖÃÚµÄÒ©ÎïÒÔ·¢»Ó¸ü¼ÑµÄÁÆÐ§ÖµµÃ½øÒ»²½Ì½ÌÖ¡£ ²Î ¿¼ ÎÄ Ï×

£Û1£Ý G¨®rska R, Gregorek H, Kowalski J, et al. Relationship between clinical parameters and cytokine profiles in inflamed gingival tissue and serum samples from patients with chronic periodontitis. J Clin Periodontol£¬2003£¬30(12):1046-1052.

£Û2£Ý Kantarci A, Hasturk H, Van Dyke TE. Host-mediated resolution of inflammation in periodontal diseases. Periodontol£¬2006£¬40:144-63.

£Û3£Ý ²Ü²É·½.ÑÀÖܲ¡Ñ§.±±¾©:ÈËÃñÎÀÉú³ö°æÉç,2000:120.

£Û4£Ý Deo V, Bhongade ML. Pathogenesis of periodontitis:role of cytokines in host response. Dent Today, 2010,29(9):60-62, 64-66.

£Û5£Ý Yoshimura A, Hara Y, Kaneko T, et al. Secretion of IL-1 beta, TNF-alpha, IL-8 and IL-1ra by human polymorphonuclear leukocytes in response to lipopolysaccharides from periodontopathic bacteria. J Periodontal Res,1997,32(3):279-286.